GB201019525D0 - Oil-based formulations - Google Patents
Oil-based formulationsInfo
- Publication number
- GB201019525D0 GB201019525D0 GB201019525A GB201019525A GB201019525D0 GB 201019525 D0 GB201019525 D0 GB 201019525D0 GB 201019525 A GB201019525 A GB 201019525A GB 201019525 A GB201019525 A GB 201019525A GB 201019525 D0 GB201019525 D0 GB 201019525D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- prodrug
- gut lumen
- oil
- premature
- premature hydrolysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 4
- 239000000651 prodrug Substances 0.000 abstract 4
- 230000002028 premature Effects 0.000 abstract 3
- 230000007062 hydrolysis Effects 0.000 abstract 2
- 238000006460 hydrolysis reaction Methods 0.000 abstract 2
- PTGORADDWDXBFH-UHFFFAOYSA-N 2-aminobenzoic acid;carbamic acid Chemical compound NC(O)=O.NC1=CC=CC=C1C(O)=O PTGORADDWDXBFH-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to the use of oil based delivery vehicles to prevent undesirable premature hydrolysis of phenolic amino benzoic acid carbamate prodrugs, while resident in the gut lumen. Preclusion of water and hydrolytic enzymes prior to prodrug absorption ensures that such compounds can be fully absorbed intact without undergoing unintended premature hydrolysis in the gastrointestinal tract so maximizing the benefit of improved systemic availability afforded by the prodrug. Furthermore judicious selection of oil and prodrug salt form can result in a sustained release plasma PK profile. The avoidance of premature degradation and release of active drug into the gut lumen minimizes any potential for a direct adverse interaction within the gut lumen.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201019525A GB201019525D0 (en) | 2010-11-18 | 2010-11-18 | Oil-based formulations |
| PCT/GB2011/052262 WO2012066347A1 (en) | 2010-11-18 | 2011-11-18 | Oil based formulations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201019525A GB201019525D0 (en) | 2010-11-18 | 2010-11-18 | Oil-based formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201019525D0 true GB201019525D0 (en) | 2010-12-29 |
Family
ID=43431636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB201019525A Ceased GB201019525D0 (en) | 2010-11-18 | 2010-11-18 | Oil-based formulations |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201019525D0 (en) |
| WO (1) | WO2012066347A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019007441A1 (en) * | 2017-07-04 | 2019-01-10 | 山东丹红制药有限公司 | Sustained release suspension containing dezocine analogue ester and preparation method therefor |
| EP3946547A4 (en) * | 2019-03-26 | 2023-01-18 | Pocket Naloxone Corp. | Devices and methods for delivering pharmaceutical compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2589993C (en) * | 2004-12-09 | 2012-07-03 | Insys Therapeutics, Inc. | Room-temperature stable dronabinol formulations |
| GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
| US9056050B2 (en) * | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| CN102625700A (en) * | 2009-07-23 | 2012-08-01 | 夏尔有限责任公司 | Galantamine amino acid and peptide prodrugs and uses thereof |
| WO2011133151A1 (en) * | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Compositions comprising enzyme-cleavable phenol-modified opioid prodrugs and inhibitors thereof |
-
2010
- 2010-11-18 GB GB201019525A patent/GB201019525D0/en not_active Ceased
-
2011
- 2011-11-18 WO PCT/GB2011/052262 patent/WO2012066347A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012066347A1 (en) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259334B1 (en) | Biodegradable lipids for the delivery of active agents | |
| IL208260A0 (en) | Nanoparticles for targeted delivery of active agents to the lung | |
| WO2011163594A3 (en) | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | |
| AR081678A1 (en) | METHODS AND COMPOSITIONS FOR INTRATECAL ADMINISTRATION OF ARISULFATASE A | |
| SG176687A1 (en) | Solid compositions comprising 5-aminolevulinic acid | |
| WO2011012816A3 (en) | Pharmaceutical formulation | |
| WO2011113013A3 (en) | Methods and compositions for treating viral or virally-induced conditions | |
| IL222548A (en) | Hydroxamic acid derivatives and pharmaceutical compositions and antimicrobial agents comprising the same | |
| WO2011112229A3 (en) | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | |
| WO2011051354A3 (en) | Transdermal pharmaceutical compositions comprising active agents | |
| EP2419138A4 (en) | Gel compositions for administration of pharmaceutically active compounds | |
| NZ592647A (en) | Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester | |
| WO2012002687A3 (en) | Methods for treating bipolar disorder | |
| EP3677261B8 (en) | Administration of serine protease inhibitors to the stomach | |
| WO2012040331A3 (en) | Multistage nanoparticles | |
| PL2585041T3 (en) | Taste-masked pharmaceutical formulation having accelerated onset of action | |
| IL205313A0 (en) | Pharmaceutical formulation of clavulanic acid | |
| EP2928462A4 (en) | METHODS OF ADMINISTERING COMPOSITIONS COMPRISING DOCOSAPENTAENOIC ACID | |
| GB201019525D0 (en) | Oil-based formulations | |
| MX346316B (en) | Pharmaceutical or neutraceutical formulation. | |
| WO2012074830A3 (en) | Modified release tranexamic acid formulation | |
| WO2013068960A3 (en) | Monounsaturated fatty acid for nailcare | |
| WO2013033602A3 (en) | Fatty acid amides, compositions and methods of use | |
| EP2247569A4 (en) | Acid salt of tolterodine having effective stability for transdermal drug delivery system | |
| MX2015006011A (en) | Medicinal lozenge based on ibuprofen sodium dihydrate. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |